Repligen, an innovative leader in bioprocess technology, has made a strategic move by acquiring essential upstream Process Analytical Technology (PAT) assets from 908 Devices for a total of $70 million. This acquisition should be viewed as more than just a simple addition of technology; it
The pharmaceutical industry is abuzz with excitement over a new class of cancer drugs known as PD-1/VEGF inhibitors. These promising therapies, currently undergoing clinical trials, might leapfrog Merck & Co.’s highly successful cancer immunotherapy, Keytruda. The advent of these new drugs could
The telehealth and telecare industries are experiencing unprecedented transformations driven by shifts in leadership, rapid technological advancements, and ongoing legal challenges. These elements are collectively redefining the landscape of healthcare delivery, compelling companies to adapt and
Fosun Pharmaceutical, a leading Chinese pharmaceutical conglomerate, recently attempted to take full control of its biopharma subsidiary, Henlius Biotech, by purchasing the remaining minority shares. This strategic move aimed to consolidate Henlius under Fosun's complete ownership, leveraging the
The Contract Development and Manufacturing Organization (CDMO) sector is navigating a landscape marked by significant changes and evolving trends. Gil Roth, President of the Pharma & Biopharma Outsourcing Association, provides a comprehensive analysis of the sector's current state and future
The healthcare investment landscape has undergone significant transformations in recent years, driven by various factors including the COVID-19 pandemic, technological advancements, and strategic shifts within the industry. As we delve into 2024, it is crucial to understand the key trends and
